請輸入關鍵字
top
YH003
2021.01.12

藥物名稱:YH003(CD40)

階段:臨床I期/II期

適應癥:I期實體瘤;II期黑色素瘤,胰腺癌


開展地區:澳大利亞

試驗名稱: A Multicenter, Open-Label, Phase I/II Dose Escalation and Expansion  Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of YH003 in combination with Toripalimab (anti-PD-1 mAb) in Subjects with Advanced Solid Tumors

試驗鏈接:https://clinicaltrials.gov/ct2/show/NCT04481009